We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.12% | 88.28 | 88.26 | 88.27 | 89.17 | 88.28 | 88.40 | 97,025 | 09:20:40 |
From Apr 2021 to Apr 2024
By Cecilia Butini
Sanofi SA said Wednesday that net profit and sales fell for the first quarter of 2021.
The French pharmaceutical major posted net profit of 1.57 billion euros ($1.90 billion), down from EUR1.68 billion a year earlier, on sales that fell to EUR8.59 billion from EUR8.97 billion.
Sales of key growth driver Dupixent grew 45.6% in the quarter despite the adverse environment created by the coronavirus pandemic, Sanofi said.
Business net income--a key profit metric that excludes some items--came in at EUR2.02 billion, compared with EUR2.04 billion. Business earnings per share were EUR1.61, a 5.2% increase from a year earlier.
The company backed its outlook for 2021, saying that it expects business earnings per share to grow by a high-single digit at constant exchange rates, barring unforeseen events.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 28, 2021 02:08 ET (06:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
